Skip to main content
B

Beijing Biostar Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 2563 HKEX Manufacturing
Open in API
Filings indexed 95 across all filing types
Latest filing 2026-04-28 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 2563

About Beijing Biostar Pharmaceuticals Co., Ltd.

http://www.biostar-pharm.com

Beijing Biostar Pharmaceuticals Co., Ltd. is a high-tech biopharmaceutical company specializing in the research, development, production, and commercialization of innovative oncology drugs. The company leverages synthetic biology technology, utilizing proprietary platforms such as combinatorial biosynthesis and microbial fermentation production to develop novel anti-cancer treatments. Its core product, Utidelone, is the subject of global clinical trials targeting various solid tumors, including advanced gastric cancer, advanced ovarian cancer, and breast cancer (including triple-negative breast cancer and brain metastasis). Utidelone has also received FDA Orphan Drug Designation for pancreatic cancer, reflecting the company's focus on addressing cancers with high unmet medical needs.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 1% confidence The document is a notice listing the Company’s board of directors and their committee roles, noting changes effective from a resignation. It is an announcement regarding changes and composition of the board and its committees. This aligns with the “Board/Management Information” category (MANG).
2026-04-28 English
RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; NON-COMPLIANCE WITH THE LISTING RULES; AND PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 1% confidence The document is an official announcement to the Hong Kong Stock Exchange regarding the resignation of an independent non-executive director and the proposed appointment of a new independent non-executive director, including board committee changes. This clearly falls under announcements of board or senior management changes. Hence it is classified as Board/Management Information.
2026-04-28 English
Annual Report 2025
Regulatory Filings
2026-04-28 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is an HKEX monthly return (Form FF301) detailing movements in authorised share capital, issued shares, public float sufficiency, and confirmations under Chapter 19B of the Exchange Listing Rules. It is a routine regulatory submission rather than an annual/quarterly report, earnings release, or specific transaction announcement. It does not announce a specific M&A, dividend, or financing event, nor is it a full financial report or proxy statement. Therefore it best fits the fallback category for miscellaneous regulatory filings: RNS.
2026-04-08 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 1% confidence The document is an “Annual Results Announcement” for the year ended December 31, 2025, published on the Hong Kong Stock Exchange. It provides audited consolidated financial highlights (revenue, profit/loss, EPS), comparative year-on-year figures, and a Management Discussion & Analysis section. It is an initial announcement of periodic financial results rather than a full annual report (10-K) or an investor presentation. Therefore it best fits the “Earnings Release” category. FY 2025
2026-03-31 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 1% confidence The document is a comprehensive announcement of the audited consolidated results for the year ended December 31, 2025, including financial highlights, MD&A, and comparative figures. It is clearly an Annual Results Announcement rather than the full statutory Annual Report (10-K) or a brief publication notice (RPA). It provides key financial metrics, commentary by management, and business review, which aligns with an Earnings Release – the initial detailed release of periodical (in this case annual) results. Therefore, it best fits the Earnings Release category (ER). FY 2025
2026-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.